Senti Biosciences (NASDAQ:SNTI - Get Free Report)'s stock had its "buy" rating reiterated by analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock. Chardan Capital's price objective points to a potential upside of 361.54% from the company's current price.
Separately, Laidlaw began coverage on Senti Biosciences in a research note on Friday, June 6th. They issued a "buy" rating and a $5.00 target price on the stock.
View Our Latest Analysis on SNTI
Senti Biosciences Stock Performance
SNTI traded down $0.26 on Thursday, hitting $2.60. The company had a trading volume of 94,636 shares, compared to its average volume of 805,885. The stock has a fifty day moving average price of $3.37 and a 200-day moving average price of $3.84. Senti Biosciences has a 12-month low of $1.52 and a 12-month high of $16.94. The stock has a market capitalization of $67.81 million, a price-to-earnings ratio of -0.17 and a beta of 2.23.
Senti Biosciences (NASDAQ:SNTI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The business had revenue of $1.30 million during the quarter, compared to the consensus estimate of $1.30 million. Analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.
Institutional Investors Weigh In On Senti Biosciences
Large investors have recently modified their holdings of the business. Renaissance Technologies LLC purchased a new stake in shares of Senti Biosciences during the fourth quarter worth about $181,000. Virtu Financial LLC purchased a new stake in shares of Senti Biosciences during the fourth quarter worth about $47,000. Nantahala Capital Management LLC purchased a new stake in shares of Senti Biosciences during the first quarter worth about $2,984,000. Finally, Heights Capital Management Inc. purchased a new stake in shares of Senti Biosciences during the first quarter worth about $2,520,000. Hedge funds and other institutional investors own 25.73% of the company's stock.
About Senti Biosciences
(
Get Free Report)
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Read More
Before you consider Senti Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.
While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
